Zobrazeno 1 - 4
of 4
pro vyhledávání: ''
Autor:
Kacper Maksymilian Mil, Mateusz Maciejczyk, Małgorzata Ewa Gryciuk, Cezary Pawlukianiec, Małgorzata Żendzian-Piotrowska, Anna Zalewska
Publikováno v:
Pharmaceuticals, Vol 13, Iss 240, p 240 (2020)
Pharmaceuticals
Volume 13
Issue 9
Pharmaceuticals
Volume 13
Issue 9
Meloxicam is a non-steroidal anti-inflammatory drug, which has a preferential inhibitory effect to cyclooxyganase-2 (COX-2). Although the drug inhibits prostaglandin synthesis, the exact mechanism of meloxicam is still unknown. This is the first stud
Autor:
Chiara Corti, Paolo Tarantino, Federica Giugliano, Matteo Repetto, Giuseppe Curigliano, Gabriele Antonarelli
Publikováno v:
Pharmaceuticals
Pharmaceuticals, Vol 14, Iss 884, p 884 (2021)
Pharmaceuticals, Vol 14, Iss 884, p 884 (2021)
Solid tumors adopt multiple mechanisms to grow, evade immune responses, and to withstand therapeutic approaches. A major breakthrough in the armamentarium of anti-cancer agents has been the introduction of monoclonal antibodies (mAbs), able to inhibi
Publikováno v:
Pharmaceuticals, Vol 14, Iss 23, p 23 (2021)
Pharmaceuticals
Volume 14
Issue 1
Pharmaceuticals
Volume 14
Issue 1
The BRAF V600E mutation leads to constitutive activation of the mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase (ERK) pathway and its downstream effector responses. Uncovering the hidden downstream effectors can aid in u
Publikováno v:
Pharmaceuticals
Pharmaceuticals, Vol 3, Iss 7, Pp 2238-2247 (2010)
Pharmaceuticals, Vol 3, Iss 7, Pp 2238-2247 (2010)
The incidence of prostate cancer increases with age and because of its high prevalence this disease has become a major public health concern. Despite advances in our understanding of the biological mechanisms responsible for the development of this c